anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a drug for treating scapulohumeral periarthritis. The common symptoms of the scapulohumeral periarthritis are omodynia and dyskinesia. The right shoulder morbidity is a little higher than the left shoulder; the scapulohumeral periarthritis is related to deficiency of qi and blood, and wind-cold damp pathogen hit or trauma strain, and has an acute pain stage and a chronic stiffness stage; the deltoideus triangularis shrinks a little in physical examination; and the trapezius cramps, shoulder osteoporosis or supraspinatus tendon and shoulder peak decline capsule calcification can be seen through an X-ray pain film. The inventor finally finds out the traditional Chinese medicine oral drug with a better curative effect for treating scapulohumeral periarthritis by a long-range research and clinical verification. The dosage of the drug component disclosed by the invention is fumbled by the inventor; the optimum proportions are 30 parts of rehmannia glutinosa, 15 parts of cornu cervi degelatinatum, 9 parts of cassia twig, 9 parts of baked ginger, 9 parts of ephedra, 10 parts of semen brassicae, 10 parts of zedoary, 10 parts of myrrh, 10 parts of notopterygium root and 6 parts of honey-fried licorice root. By adopting these drug compositions, each drug generates the synergistic effect, and the drug has the effects of warming and promoting channels, promoting the circulation of qi and removing stasis, and promoting blood circulation to arrest pain, so as to effectively treat the scapulohumeral periarthritis.
The present invention is an endovascular embolic composition. The embolic composition comprises a hydrophilic insoluble matrix having a microscopic mesh-like structure. The voids or intricacies of the matrix enclose droplets of aqueous solution as well as liquid oil. This structure is essentially equivalent to a "gel" structure with the insoluble matrix including both aqueous and oil droplets within its mesh. In creating the matrix a liquid oil base is mixed with an aqueous solution of a matrix base. The matrix base comprises an organic polymer such as a protein like albumin or its equivalent dissolved in an aqueous solution which may contain additional solutes. The matrix base solution is mixed and emulsified with the liquid oil base at a volume ratio ranging between about 1-to-1 and 1-to-5 respectively. To create the embolic composition the matrix base is then precipitated or cross-linked to form a gel with a mesh-like microscopic structure in which insoluble matrix surrounds and entraps both aqueous fluid and liquid oil. Preferably sclerifying agents are included within the composition so that scar tissue will develop to permanently occlude the embolized vasculature.
This study is a prospective and single-center trial in China.It intends to enroll 216 patients with coronary artery disease whose coronary artery is determined to be 30-90% stenosis after coronary CT scan. CT image data will be imported for CT-QFR detection and undergo coronary angiography within 30 days. Quantitative analysis of coronary angiography (QCA) was performed with the degree of coronary stenosis. FFR and QFR were detected during the operation. Use FFR as a reference standard to verify the diagnostic performance of CT-QFR and QFR. The primary endpoint is the diagnostic accuracy of CT-QFR in identifying hemodynamically significant coronary stenosis with FFR as the reference standard. Major secondary endpoint is the non-inferiority of CT-QFR compared with QFR in the patients without extensively calcified lesions. The completion of the project will provide patients with a practical non-invasive assessment method of coronary heart disease which provides the best treatment strategy.
Soybean phytophthora blight is a severe menace to global agriculture, causing annual losses surpassing USD 1 billion. Present crop loss mitigation strategies primarily rely on chemical pesticides and disease-resistant breeding, frequently surpassed by the pathogens' quick adaptive evolution. In this urgent scenario, our research delves into innovative antimicrobial peptides characterized by low drug resistance and environmental friendliness. Inhibiting chitin synthase gene activity in Phytophthora sojae impairs vital functions such as growth and sporulation, presenting an effective method to reduce its pathogenic impact. In our study, we screened 16 previously tested peptides to evaluate their antimicrobial effects against Phytophthora using structure-guided drug design, which involves molecular docking, saturation mutagenesis, molecular dynamics, and toxicity prediction. The in silico analysis identified AMP_04 with potential inhibitory activity against Phytophthora sojae's chitin synthase. Through three rounds of saturation mutagenesis, we pin-pointed the most effective triple mutant, TP (D10K, G11I, S14L). Molecular dynamic simulations revealed TP's stability in the chitin synthase-TP complex and its transmembrane mechanism, employing an all-atom force field. Our findings demonstrate the efficacy of TP in occupying the substrate-binding pocket and translocation catalytic channel. Effective inhibition of the chitin synthase enzyme can be achieved. Specifically, the triple mutant demonstrates enhanced antimicrobial potency and decreased toxicity relative to the wild-type AMP_04, utilizing a mechanism akin to the barrel-stave model during membrane translocation. Collectively, our study provides a new strategy that could be used as a potent antimicrobial agent in combatting soybean blight, contributing to sustainable agricultural practices.
Evidence suggests that risk factors for atherosclerosis contribute to atherogenesis by causing endothelial injury. However, little is known about determinants of endothelial cell repair and regeneration. We propose that mobilization of endothelial progenitor cells (EPCs) constitutes one mechanism for ongoing endothelial repair. EPCs are a bone marrow derived cell population that can be isolated from peripheral blood. Among human peripheral mononuclear cells, EPCs are relatively abundant with an estimated frequency of 1 in 500 to 1 in 1000 cells. Evidence suggests that EPCs can participate in angiogenesis under pathophysiological circumstances. Under normal conditions, however, adult organisms undergo little if any active angiogenesis. One explanation for this set of observations is that high circulating levels of EPCs may exist to allow these cells to participate in functions beyond angiogenesis. We hypothesize that one such function is in the repair of ongoing endothelial injury. To test this hypothesis, we will measure peripheral blood EPC activity by ascertaining the number of EPC colony forming units from peripheral blood sampling. We intend to correlate this biological determinant with the degree of endothelial dysfunction assessed by flow-mediated brachial artery reactivity, and an atherosclerotic risk stratification method developed by the Framingham study. We hypothesize that a correlation will exist between the atherosclerotic risk profile, endothelial function and EPC activity and that the EPC activity will therefore become a novel surrogate biological marker for cumulative cardiovascular risk.
Neomycin and polymyxin B sulfates and gramicidin ophthalmic solution, USP is a sterile antimicrobial solution for ophthalmic use.

Each mL contains: Actives: neomycin sulfate, (equivalent to 1.75 mg neomycin base), polymyxin B sulfate equal to 10,000 polymyxin B units, gramicidin, 0.025 mg; Inactives: sodium chloride, alcohol (0.5%), Poloxamer 188, propylene glycol, purified water. Hydrochloric acid and/or ammonium hydroxide may be added to adjust pH (4.7-6.0).

Preservative: thimerosal 0.001%.

Neomycin Sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 micrograms of neomycin base per milligram, calculated on an anhydrous basis.

The structural formulae are:

Polymyxin B Sulfate is the sulfate salt of polymyxin B1 and B2 which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per milligram, calculated on an anhydrous basis. The structural formulae are:

Gramicidin (also called gramicidin D) is a mixture of three pairs of antibacterial substances (Gramicidin A, B and C) produced by the growth of Bacillus brevis Dubos (Fam. Bacillaceae). It has a potency of not less than 900 mcg of standard gramicidin per mg. The structural formulae are:
PROBLEM TO BE SOLVED: To provide a system, method, apparatus, and computer readable medium configured for monitoring a user performing an athletic movement and/or exercise and generating a fatigue value.SOLUTION: Fatigue values may be determined for different groups. In one embodiment, a first value is determined for a muscle fatigue value and a second value is determined for a respiratory value. In another embodiment, a first value may pertain to a first muscle group and a second value may pertain to a second muscle group. A fatigue index may be created from values obtained during an athletic movement and/or a workout session. In further embodiments, a cumulative fatigue index may be determined. A cumulative fatigue index may consider values obtained during several workout sessions. Further, data obtained outside workout sessions may be considered in determinations relating to fatigue values and/or indices.SELECTED DRAWING: Figure 13
Patients in the control condition will be assigned to a wait-list (duration 4 months). During waiting time, clinical services will be provided as needed (excluding TF-CBT).
Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue at times of risk of infection. The compositions can contain elevated antibody titers for several specific pathogens including S. aureus, CNS, Enterococci, S. epidermidis, P. aeruginosa, E. coli, and Enterobacter spp., etc. The compositions are applied directly to a wound or burn site as an ointment, creme, fluid, spray, or the like, prior to viral or bacterial attachment or biofilm formation such that adhesion of the pathogens is inhibited and the pathogens closest to the wound or burn site will be pre-opsonized for phagocytic killing prior to toxin release. The immunoglobulins in the composition can be immobilized on a biocompatible material such as collagen, fibrin, hyaluronan, biodegradable polymers, and fragments thereof, which will be placed in-situ at the wound, surgical or burn site. In addition, the immunoglobulins in the composition may be coated on the body contacting surface of an implantable device such as a catheter, contact lens or total joint. The inventive compositions have particular application in preventing infections.
PURPOSE:To obtain the titled drug useful for skin diseases or hemorrhoids in a short time without passing through an extraction step, by drying a raw  Hottuynia cordata Thunb., crushing the dried herb into pieces, and finely  pulverizing the resultant pieces. CONSTITUTION:A raw Hottuynia cordate Thunb. is dried in the preliminary and the regular drying steps, crushed to pieces and finely pulverized to give a powdery pharmaceutical of the Hottuynia cordata Thunb. The preliminary drying step is carried out by hanging the raw leaf of the Hottuynia cordata Thunb. in a vinyl greenhouse, etc. at 30-50 deg.C usually for about 2 days. The main drying is carried out by allowing the preliminarily dried leaf in a dryer at 80-100 deg.C usually for about 2 days. The moisture in the raw leaf is volatilized by the preliminary drying to reduce the bulkiness thereof, and the main drying is simplified in a shortened time. The dried Hottuynia cordate Thunb. has no bad smell as in the raw leaf, and is suitable for internal use with the unique fragrance retained. The finely pulvevized leaf has good fluidity as a powder, and very convenient for giving the constant amount of the dosage unit.
The invention relates to a pharmaceutical composition for treating diarrhea, as well as a preparation method and applications of the composition, and in particular relates to a pharmaceutical composition for treating the diarrhea. The pharmaceutical composition for treating the diarrhea consists of elsholtzia volatile oil, a honeysuckle leaf ethyl alcohol-water extractive, a cherokee rose root water extractive and a poria cocos water extractive. The pharmaceutical composition consists of the following components measured in parts by weight according to crude materials: 5-167 parts of elsholtzia, 2.5-80 parts of honeysuckle leaves, 4.2-80 parts of cherokee rose roots and 2.5-100 parts of poria cocos. The pharmaceutical composition can be used for treating the diarrhea of mammals without obvious toxic and side effects. The invention also relates to the preparation method of the pharmaceutical composition and a pharmaceutical preparation for treating the diarrhea. The pharmaceutical preparation for treating the diarrhea comprises an effective treatment amount of pharmaceutical composition disclosed by the innvetion as an active ingredient, and one or more pharmaceutically acceptable carriers.
Subjects from 3 months to 2 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort C reviewed by the IDMC.
A system and method for managing and tracking home health care workers is provided. A graphical user interface (GUI) implanted on a network of computing devices is provided for a management and performance platform. The platform provides utility for scheduling and monitoring tasks to be performed by a caregiver during a shift or visit to a remote location such as a client's home. The tasks performed by a caregiver are based on a plan that a clinical nurse or other supervising medical personnel establishes ahead of time prior to the caregiver visit. As caregivers log in on their remote device, a timestamp is captured and recorded that reflects the “Clock in” time for a time sheet record. As tasks are completed (or attempted), additional timestamps are captured and recorded. Documentation is generated from the captured information and used for timesheets, payroll, insurance billing, and medical record keeping.
BACKGROUND: Motor-sparing local infiltration analgesia (LIA) enhances recovery after total hip arthroplasty (THA) and total knee arthroplasty (TKA). However, LIA can induce local anesthetic systemic toxicity (LAST), sometimes necessitating rescue lipid emulsion therapy. Our institute initiated a pilot study to pretreat patients with lipid emulsion (SMOFlipid®) to test its efficacy in mitigating LIA-induced LAST events.
METHODS: This retrospective study enrolled 1,621 adult patients who received LIA with bupivacaine (2-3 mg/kg, maximum 300 mg) for unilateral primary THA or TKA under general anesthesia between January 2020 and April 2022. A total of 439 patients received lipid pretreatment, while 1,182 did not. Demographics, surgical and anesthesia profiles, along with LAST events affecting the neurological, cardiovascular, and respiratory systems, were compared after propensity score matching for age, sex, body mass index (BMI), and surgery type.
RESULTS: The incidence of severe LAST events requiring rescue lipid emulsion slightly decreased after lipid pretreatment (from 2.54 to 2.28 per 1000). Lipid pretreatment significantly reduced the incidence of bradycardia and new-onset arrhythmia (odds ratio: 0.13, adjusted p-value: 0.024) but increased postoperative opioid requirement (odds ratio: 1.71, adjusted p-value: 0.032) after Benjamini-Hochberg correction for multiplicity.
CONCLUSIONS: The efficacy of lipid pretreatment (SMOFlipid® 1.5 ml/kg, maximum 100 ml) in mitigating LIA-induced LAST remains controversial. While lipid pretreatment reduced the incidence of new-onset arrhythmia, it showed no clear benefits for neurologic and respiratory outcomes. Additionally, lipid pretreatment might hinder postoperative recovery by increasing the need for rescue opioid analgesia. Further prospective pharmacokinetic studies are required to assess plasma bupivacaine concentrations following LIA and lipid pretreatment, examine their relationship to LAST events, and establish the efficacy and safety of lipid pretreatment.
Subjects meeting the inclusion criteria were randomly assigned to 2 groups (Vigiis 101 lactic acid bacteria: n = 50, placebo: n = 50) in a 1:1 ratio, Block : 4 randomization. Randomization was performed by a research statistician not directly involved in the trial. Researchers and subjects were unaware of treatment groups until data analysis was complete.

During the 12-week use trial, subjects were asked to take Vigiis 101 Lactobacillus capsules or a placebo once a day before breakfast. The subjects were required to maintain a regular lifestyle and recorded daily Vigiis 101 Lactobacillus or placebo consumption, diet and the number of steps walked as a measure of physical activity. Body composition, anthropometric and biochemical measurements were measured at weeks 0, 4, 8, and 12 after consumption initiation. Clinical exams are done every 4 weeks in the hospital. Subjects filled out daily diaries that included questions about study product intake, other food intake, number of bowel movements, stool quality (consistency and color), any medications received, and any uncomfortable symptoms such as diarrhea, constipation, Vomiting, flatulence, discomfort, etc.
The invention concerns a DNA sequence for the genetic therapy of tumours. The essential components of the DNA sequence consist of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated cell-specifically in proliferating endothelium cells or cells neighbouring these endothelium cells. The promoter module regulates this activation specifically according to the cell cycle. The active substance is an angiogenesis inhibitor or a cytostatic or cytotoxic molecule. The DNA  sequence is introduced into a viral or non-viral vector, supplemented by a ligand having affinity for the activated endothelium cell.
The Biogen Multiple Sclerosis Pregnancy Exposure Registry is a prospective, observational registry designed to evaluate pregnancy outcomes in women with multiple sclerosis (MS) who were exposed to a Registry-specified Biogen Multiple Sclerosis product during the eligibility window for that product. Women of childbearing potential are a considerable segment of the patient population affected by MS and are likely to be exposed to a Registry-specified Biogen MS product around the time of conception and during pregnancy. Biogen completed pregnancy registries for Avonex and Tysabri; however, formal studies in pregnant women have not been conducted. Therefore, it is important to evaluate, in a global Pregnancy Registry, how exposure to a marketed Biogen MS product specified in this Pregnancy Registry may affect pregnancy and infant outcomes. Data will be collected on prospective pregnancies (i.e. enrollment prior to knowledge of outcome) at time of enrollment, 6 to 7 months gestation, and approximately 4,12, and 52 weeks after estimated date of delivery. The prevalence of spontaneous abortions, birth defects, and other pregnancy and infant outcomes will be calculated and compared to background rates from external sources such as the European Surveillance of Congenital Anomalies.
BACKGROUND: Preclinical experiments suggest protective effects of omega-3 fatty acids and their metabolites in lung injury and fibrosis. Whether higher intake of omega-3 fatty acids is associated with disease progression and survival in humans with pulmonary fibrosis is unknown.
RESEARCH QUESTION: What are the associations of plasma omega-3 fatty acid levels (a validated marker of omega-3 nutritional intake) with disease progression and transplant-free survival in pulmonary fibrosis?
STUDY DESIGN AND METHODS: Omega-3 fatty acid levels were measured from plasma samples of patients with clinically diagnosed pulmonary fibrosis from the Pulmonary Fibrosis Foundation Patient Registry (n = 150), University of Virginia (n = 58), and University of Chicago (n = 101) cohorts. The N-3 index (docosahexaenoic acid + eicosapentaenoic acid) was the primary exposure variable of interest. Linear-mixed effects models with random intercept and slope were used to examine associations of plasma omega-3 fatty acid levels with changes in FVC and diffusing capacity for carbon monoxide over a period of 12 months. Cox proportional hazards models were used to examine transplant-free survival. Stratified analyses by telomere length were performed in the University of Chicago cohort.
RESULTS: Most of the cohort were patients with idiopathic pulmonary fibrosis (88%) and male patients (74%). One-unit increment in log-transformed N-3 index plasma level was associated with a change in diffusing capacity for carbon monoxide of 1.43 mL/min/mm Hg per 12 months (95% CI, 0.46-2.41) and a hazard ratio for transplant-free survival of 0.44 (95% CI, 0.24-0.83). Cardiovascular disease history, smoking, and antifibrotic usage did not significantly modify associations. Omega-3 fatty acid levels were not significantly associated with changes in FVC. Higher eicosapentaenoic acid plasma levels were associated with longer transplant-free survival among University of Chicago participants with shorter telomere length (P value for interaction = .02).
INTERPRETATION: Further research is needed to investigate underlying biological mechanisms and whether omega-3 fatty acids are a potential disease-modifying therapy.
PROBLEM TO BE SOLVED: To obtain a hair-styling composition capable of keeping a soft and natural hair style over a long period, by incorporating an emulsion-polymerized crosslinked silicone material emulsion having a specific crosslinking level into the composition. SOLUTION: This hair-styling composition contains (i) 0.1-1.0wt.% of a non- rigid emulsion-polymerized crosslinked silicone polymer, (ii) 0.1-1.0wt.% of a hair-styling polymer, (iii) 0.01-5wt.% of a surfactant, (iv) water and (v) 0-30wt.% of an aerosol propellent. The ratio of branched monomer unit in the component (i) is 0.05-10wt.% and the component (i) is preferably a crosslinked dimethiconol. The component (ii) can be used in combination with a nonionic hair-styling polymer and is e.g. a copolymer of vinylpyrrolidone and vinyl acetate. The composition can be prepared in the form of cream, gel, mousse, especially aerosol. and gives remarkable hair-style and sensual feeling.
Successful surgical management of a chronic complex abdominal fistula requires thoughtful pre-operative evaluation and planning and often benefits from a multi-disciplinary approach. Initially, attention is focused on controlling sepsis and ensuring adequate hydration and electrolyte replacement. Next, efforts to optimize nutrition and engage the patient in prehabilitation are prioritized. Simultaneously, imaging is used to gain detailed assessment of anatomy. We present a challenging case involving a Jackson-Pratt (JP) drain from prior surgery causing a complex intra-abdominal fistula. The JP drain traversed multiple small bowel loops and the sigmoid colon before terminating in the bladder. Management required multi-disciplinary coordination involving colorectal surgery and urology. The patient's definitive surgery included anterior resection, colostomy takedown, right colectomy, three small bowel resections, and bladder repair. The use of JP drains after abdominal surgery is not without risk. Clinicians should have standardized indications for placement of JP drains and consistent protocols regarding timing of removal.